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Abstract
The neocortex contains an unparalleled diversity of neuronal subtypes, each defined by distinct
traits that are developmentally acquired under the control of subtype-specific and pan-neuronal
genes. The regulatory logic that orchestrates the expression of these unique combinations of genes
is unknown for any class of cortical neuron. Here, we report that Fezf2 is a selector gene able to
regulate the expression of gene sets that collectively define mouse corticospinal motor neurons
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(CSMN). We find that Fezf2 directly induces the glutamatergic identity of CSMN via activation of
Vglut1 (Scl17a7) and inhibits a GABAergic fate by repressing transcription of Gad1. In addition,
we identify the axon guidance receptor Ephb1 as a target of Fezf2 necessary to execute the
ipsilateral extension of the corticospinal tract. Our data indicate that co-regulated expression of
neuron subtype–specific and pan-neuronal gene batteries by a single transcription factor is one
component of the regulatory logic responsible for the establishment of CSMN identity.
During development, neurons of the CNS acquire distinct molecular, anatomical and
physiological properties. Development of these traits is dictated by pan-neuronal and
lineage-specific molecular cues, which in combination define neuronal subtype–specific
identity and set the basis for neuronal diversity.
Among other regions of the mammalian CNS, the cerebral cortex stands as a prime example
of how expanded neuronal diversity served the evolution of complex behavior. Here an
extraordinary number of neuronal subtypes integrate into local and long-distance circuitry
subserving sensory, motor and high-level cognitive functions1. The majority of cortical
neurons are excitatory projection neurons. Their classification is largely based on axonal
projection targets, but it is clear that multiple traits—molecular identity, primary and
collateral axonal connections, somatodendritic morphology and electrophysiological activity
—must be taken into account to accurately distinguish individual projection neuron
subtypes2. The molecular regulatory logic that orchestrates acquisition of multiple class-
specific features is not understood for any neuronal subtype of the cerebral cortex.
CSMN are one specialized class of cortical excitatory neurons, which connect layer Vb of
the cortex to the spinal cord. At the molecular level, CSMN are the most extensively
characterized class of cortical projection neurons3,4. A master transcription factor—
forebrain expressed zinc finger 2 (Fezf2)—has been identified that is necessary for the fate
specification of CSMN5–7. In the absence of Fezf2, CSMN fail to generate. In agreement,
CSMN-specific genes are not expressed in layer Vb of the Fezf2−/− null cortex, a deficiency
accompanied by changes in dendritic morphology and a lack of axonal projections to the
spinal cord5–7.
Conversely, Fezf2 alone can cell-autonomously instruct the acquisition of CSMN-specific
features when expressed in diverse, permissive cellular contexts in vivo. Ectopic
overexpression of Fezf2 in progenitors and postmitotic neurons of different lineages is
sufficient to induce the generation of neurons that express multiple CSMN genes and extend
axons to subcerebral targets5,8–10. Beyond acquisition of lineage-specific CSMN features,
neurons expressing Fezf2 also acquire necessary cortical pan-projection neuron features.
They become glutamatergic and develop distinctive pyramidal morphology8. These data
indicate that Fezf2 is sufficient to instruct the acquisition of multiple aspects of CSMN
identity.
Here we demonstrate that Fezf2 is a selector gene for an individual class of neurons of the
neocortex: corticospinal motor neurons. We found that activation and repression of large
batteries of genes necessary to orchestrate the acquisition of CSMN defining traits was
directly co-regulated downstream of Fezf2. Fezf2 was sufficient to induce vesicular
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glutamate transporter 1 (Vglut1) and to repress glutamate decarboxylase 1 (Gad1)
expression to instruct the acquisition of glutamatergic identity. In addition, we uncovered a
new role for EphB1 as a functionally relevant effector of Fezf2, required to execute the
ipsilateral extension of the corticospinal tract through the ventral forebrain. Our data indicate
a direct role for Fezf2 as a selector gene that coordinates the expression of pan-neuronal and
class-specific genes required for the developmental acquisition of CSMN identity.
RESULTS
Fezf2 induces signature genes of corticospinal neurons
To understand the molecular logic underlying the acquisition of CSMN traits upon Fezf2
expression, we compared the in vivo gene expression of FACS-purified cortical progenitors
that ectopically expressed Fezf2 to control progenitors. We used in utero electroporation to
deliver Fezf2GFP or CtrlGFP expression vectors to neocortical progenitors at embryonic day
(E) 14.5, when they primarily generate callosal projection neurons (CPN) of the upper layers
(Supplementary Fig. 1a). Overexpression of Fezf2 in these progenitors is sufficient to
instruct a fate switch resulting in the generation of CSMN and other subtypes of corticofugal
projection neurons5,7,11. Fezf2GFP- and CtrlGFP-electroporated progenitors were FACS-
purified 24 and 48 h after surgery (Supplementary Fig. 1b,c) and acutely profiled by
microarrays.
A large set of genes was induced by Fezf2 as early as 24 h (263 genes; P < 0.001, fold
change > 1.5), while others were induced not earlier than 48 h (441 genes; P < 0.001, fold
change > 1.5) after electroporation. In addition, we identified a smaller set of genes
repressed by Fezf2 (90 genes at 24 h; 89 genes at 48 h; P < 0.001, fold change > 1.5)
(Supplementary Table 1).
To investigate whether genes induced by Fezf2 mark developing CSMN, we performed in
situ hybridization for selected candidates (Supplementary Table 1) at multiple stages of
embryonic and postnatal development of the cerebral cortex (E15.5, E18.5, postnatal day (P)
3, P7 and P14; Fig. 1 and Supplementary Fig. 2). Remarkably, we identified a series of
Fezf2 target genes (for example, Ldb2, Adcyap1, Akap12, Ephb1, Rgs16, Rgs8, Acvr1c,
Pappa2, Kif26a) that labeled developing CSMN (and related subcerebral projection neurons,
ScPN) in the early cortical plate (Fig. 1 and Supplementary Fig. 2), whereas other targets
(for example, Kif26a, Tshz2, Tmem163, Cntn6, C1ql3, Parm1) were specific to later stages
of CSMN development (Fig. 1 and Supplementary Fig. 2).
To precisely define the neuron subtype–specific expression of the identified transcripts, we
performed colocalization analyses of all the selected Fezf2-induced genes with CTIP2, a
well-established marker of CSMN and other ScPN3. As expected, all genes tested showed
various degrees of colocalization with CTIP2 (Fig. 2 and Supplementary Fig. 3a). Among
the embryonic CSMN marker genes, Adcyap1 showed restricted expression both in cortical
progenitors at E13.5, the peak of CSMN neurogenesis, and subsequently in developing layer
V (Fig. 2a). Adcyap1 expression molecularly defined a subpopulation within the broader
group of CTIP2+ neurons (Fig. 2b). At postnatal stages, Kif26a expression similarly defined
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a subset of CTIP2+ neurons (Fig. 2c), whereas Tmem163 labeled most of the CTIP2+
population in the cortex (Fig. 2d).
To investigate whether Fezf2 is required for the expression of the identified target genes, we
performed in situ hybridization for 13 genes on Fezf2−/− cortex. We found that, in the
absence of Fezf2, the expression of all genes tested was abrogated or decreased in layer Vb.
Notably, the effect of Fezf2 loss on expression was selective for layer Vb, as these genes
were maintained in other layers (Supplementary Fig. 3b). These data indicate that Fezf2
induces numerous early and late CSMN genes and that Fezf2 is required for the expression
of its targets in layer Vb.
Fezf2 induces a transcriptome shift toward nascent CSMN
To understand how early during development Fezf2 governs expression of CSMN genes, we
interrogated our target gene list against available RNA sequencing data from E14.5 cortical
plate, subventricular zone (SVZ) and ventricular zone (VZ)12. At E14.5 the cortical plate is
mostly populated by early postmitotic corticofugal neurons (including nascent CSMN). In
contrast, the SVZ and the intermediate zone (SVZ/IZ) primarily contain basal progenitors of
upper layer CPN13–15 and early postmitotic upper layer CPN16. Finally, the VZ is mostly
populated by apical progenitors generating upper layer CPN15. We found that Fezf2
overexpression upregulated 186 genes enriched in the cortical plate versus SVZ/IZ and VZ
(Supplementary Fig. 4 and Supplementary Table 2).
We next compared the Fezf2-induced genes to the available transcriptome of purified
CSMN3. Strikingly, within 48 h, Fezf2 overexpression had already induced 30 genes known
to be restricted to early postnatal CSMN (Supplementary Table 3).
Next we investigated whether Fezf2 repressed genes of alternative neuronal fates. We found
that 73 genes repressed by Fezf2 (at both 24 and 48 h) were preferentially expressed in the
E14.5 VZ and SVZ/IZ, which mainly contain progenitors of upper layer projection neurons
(Supplementary Fig. 5 and Supplementary Table 2). In agreement, comparative analysis
with the available transcriptome of purified CPN17 showed that Fezf2 repressed 17 genes
including Cux1, Zfhx4, Fzd1 and Btbd11. These included early markers of the CPN lineage,
such as Cux2, shown to mark progenitors fated to an upper layer identity15. The data
indicate that, when expressed in progenitors of upper layer CPN, Fezf2 induces a battery of
transcripts that collectively define developing CSMN and represses genes of developing
CPN.
Fezf2 associates with the proximal promoters of CSMN genes
To elucidate the strategy used by Fezf2 to instruct CSMN identity, we performed a genome-
wide DNA binding analysis for Fezf2 in cortical progenitors, using chromatin
immunoprecipitation followed by deep sequencing (ChIP-seq)18 in combination with RNA-
seq. Cortical neural progenitors were isolated at E14.5 and expanded in vitro for one passage
as neurospheres. The neurospheres were infected with retroviruses encoding epitope-tagged
Fezf2 (3xFlag-Fezf2) or control (3xFlag) and harvested 48 h after infection for anti-Flag
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ChIP (Supplementary Fig. 6a). The 3xFlag-tagged Fezf2 was confirmed to be functional by
in utero electroporation (Supplementary Fig. 6b–e).
Two replicates of the ChIP-seq data sets were analyzed independently using the GEM
(genome-wide event finding and motif discovery) integrative computational method19. In
the two replicates, GEM analysis predicted 15,665 binding events with significant
enrichment in 3xFlag-Fezf2 over control (P < 10−3; Supplementary Table 4). Of these,
81.8% fell within 5 kb of the transcription start site (TSS) of 12,860 annotated genes (Fig. 3a
and Supplementary Table 4). Genes bound by Fezf2 contained over 63% of known CSMN
genes3 (Supplementary Table 4), including those expressed at early (Fig. 3b–c), middle (Fig.
3d) and late stages of CSMN maturation (Fig. 3e–i).
To assess the relationship between DNA binding and transcriptional regulation by Fezf2, we
performed comparative RNA-seq analysis of 3xFlag-Fezf2 and 3xFlag neurospheres 48 h
after infection (Supplementary Fig. 6a). We identified 1,295 transcripts differentially
expressed upon Fezf2 induction, including 747 upregulated and 548 downregulated genes
(false discovery rate = 10%; Supplementary Table 5). The fragments per kilobase RNA per
million mapped reads (FPKM) values of Fezf2 indicate absence of transcription (FPKM =
0.42) in control progenitors and high levels upon Fezf2 overexpression (FPKM = 3,142, data
not shown). Confirming Fezf2 overexpression in vivo, 224 of the genes induced by Fezf2 in
neurospheres were preferentially expressed in the cortical plate and were enriched for
postmitotic neuronal genes (Supplementary Fig. 7a and Supplementary Table 5). In contrast,
155 genes downregulated by Fezf2 were preferentially expressed in VZ and SVZ/IZ and
were enriched for cell-cycle genes (Supplementary Fig. 7b and Supplementary Table 5).
Genes upregulated by Fezf2 in neurospheres also showed enrichment for CSMN versus
CPN signature genes by gene score enrichment analysis (GSEA) (Fig. 3j and Supplementary
Table 4). Collectively, this indicates that Fezf2 induces similar transcriptional changes in
isolated cortical progenitors to the ones observed in vivo.
We found that 64.1% of the genes induced and 77.4% of those downregulated by Fezf2 in
cortical neurospheres were promoter-bound (Supplementary Fig. 8a,b). Similar percentages
were observed when using transcripts regulated by Fezf2 in vivo (Supplementary Fig. 8c,d).
These represent a significantly greater proportion of genes than expected by chance (Online
Methods, Supplementary Fig. 8c–e and Supplementary Table 6). GSEA analysis of genes
that were both transcriptionally regulated and promoter-bound by Fezf2, against sets of
CSMN and CPN signature genes (Supplementary Table 4), showed that only CSMN
signature genes were significantly enriched in the Fezf2-upregulated targets (Fig. 3j).
GEM motif-finding analysis identified a GC-rich sequence (CGCCGC) that is enriched at
Fezf2-bound sites (Supplementary Fig. 9a). Since Fezf2-bound promoters are slightly more
GC-rich than unbound ones (64.4% versus 49.6% GC content; Supplementary Fig. 9b), it is
difficult to conclude whether Fezf2 directly binds to this motif. Nevertheless, this sequence
was present in 42.9% of Fezf2-bound TSSs compared to 11.2% of unbound TSSs. In
addition, electrophoretic mobility shift assay on selected target promoters containing this
sequence (namely, Ascl1 and Ephb1) showed binding by Fezf2 (Supplementary Fig. 9c,d).
Previously reported consensus sequences predicted either by SELEX (systematic evolution
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of ligands by exponential enrichment) in zebrafish20 or using protein-DNA arrays in the
human protein-DNA interactome (hPDI)21 were present in 15.4% for hPDI and 3.9% for
SELEX of all Fezf2-bound sites, respectively, while the GEM-defined motif was present in
48.6% of these sites (Supplementary Fig. 9b).
Together, these data indicate that Fezf2 activates and represses a broad program of neuron
subtype–specific genes by binding to proximal promoters.
Fezf2 selects glutamatergic and represses GABAergic fate
To functionally test whether genes regulated by Fezf2 control the acquisition of CSMN
traits, we concentrated on two defining features of CSMN: glutamatergic identity and axonal
extension to the spinal cord. Glutamate signaling is a terminal, necessary feature of all
cortical projection neurons. It is unknown whether fate-specifying transcription factors for
cortical neuron classes also instruct the establishment of this pan-neuronal trait. We found
that Fezf2 bound to the promoter of Vglut1, the vesicular glutamate transporter used by most
cortical projection neurons, including CSMN22, and was sufficient to induce its expression
in cortical neurospheres (Fig. 4a,b). The binding appeared specific, as Vglut2 (Scl17a6),
used only by glutamatergic neurons in cortical layer IV and outside of the cortex22, was
neither bound nor transcriptionally regulated. Concomitantly, Fezf2 bound to the promoter
of Gad1 (Gad67), necessary for establishment of GABAergic identity, but repressed its
expression (Fig. 4a,b). To test the extent to which Fezf2 can instruct neurotransmitter
choice, we established doxycycline-inducible Fezf2-IRES-GFP (iFIG) and control GFP
(iGFP) mouse embryonic stem cell lines and induced neural differentiation using the Serum-
free embryoid body quick (SFEBq) protocol23 (Fig. 4c,d and Supplementary Fig. 10). GFP+
cells were FACS-sorted and profiled by RNA-seq. Confirming our results in primary
cortical progenitors, Fezf2 overexpression induced Vglut1, had no effect on Vglut2 and
inhibited the expression of Gad1 (Fig. 4e). Together, these data indicate that Fezf2 is
sufficient to select the appropriate effector genes to establish the neurotransmitter identity of
CSMN, while repressing an alternative GABAergic fate.
Fezf2 directly controls expression of Ephb1 in CSMN
Axonal connectivity to the spinal cord is a defining class-specific trait of CSMN. Directed
axonal extension begins soon after CSMN fate specification and is strictly guided under the
control of multiple axon guidance molecules (reviewed in ref. 24). Gene Ontology analysis
of the Fezf2-induced genes showed a significant enrichment in axon guidance molecules.
Fezf2 associated with the proximal promoters of 78% of these genes (Supplementary Table
4), including neuropilin 2 (Nrp2) [and Robo1, which are known to affect the extension and
guidance of the corticospinal tract (Supplementary Fig. 11a). Among these, we selected for
further analysis Ephb1 (Fig. 1), encoding a tyrosine kinase receptor that mediates axon
guidance and is critical for midline repulsion decisions25–27 and whose function in CSMN
remains unknown.
We first profiled Ephb1 expression in the developing cortex by in situ hybridization. Ephb1
mRNA peaked in the cortical plate at E15.5, when CSMN axonal extension begins. Ephb1
expression remained restricted to developing layer V, and at lower levels in layer VI, until
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approximately E18.5 (Fig. 5a). Postnatally, Ephb1 levels drastically decreased, and by P14
expression was weak and detectable only in layer VI (Fig. 5a) in both TBR1+ projection
neurons28 and APC+ oligodendrocytes (Fig. 5b)29.
To define the neuron subtype–specific expression of Ephb1 within layer V, we used β-
galactosidase (β-gal) as a proxy for endogenous Ephb1 expression in mice in which a lacZ
cassette has been knocked into the Ephb1 locus (see Online Methods; Supplementary Fig.
11b). Virtually all of the β-gal+ neurons were CTIP2+ and negative for SATB2, a marker for
CPN30,31 (Fig. 5c). In addition, we retrogradely labeled ScPN and CPN by injecting
FluoroGold into the pons and the contralateral hemisphere, respectively. We found that β-gal
was expressed in FluoroGold-labeled ScPN and excluded from CPN labeled from
contralateral cortex (Fig. 5c). These data demonstrate that, in the developing cortex, Ephb1
is specifically expressed in neuronal subtypes that extend ipsilateral axonal projections and
is excluded from neuronal subtypes that project through the cortical midline.
To investigate whether Fezf2 is required for Ephb1 expression, we performed in situ
hybridization on cortical sections from Fezf2−/− mice at E18.5. In the absence of Fezf2,
Ephb1 was no longer expressed in ScPN, and expression was maintained only at very
reduced levels in layer VI (Fig. 5d). In agreement, our ChIP-seq data showed that Fezf2
associates with the proximal promoter of the Ephb1 gene, within a 310-base-pair region at
the TSS (Fig. 5d and Supplementary Fig. 9d). Ephb1 expression was unchanged in the
striatum of Fezf2−/− mice, a region that does not endogenously express Fezf2 (Fig. 5d).
These data demonstrate that Fezf2 is required for the expression of Ephb1 in ScPN.
Abnormal anterior commissure axon crossing in Ephb1−/− mice
To decipher the role of EphB1 during CSMN development, we examined Ephb1−/− mice.
Brains of Ephb1−/− and wild-type littermates (P28) were processed by
immunohistochemistry for myelin basic protein to visualize myelinated axons. Mutant mice
displayed clear abnormalities of major axon tracts (Fig. 6). The internal capsule comprised
smaller than wild type and partly unfasciculated axon bundles (Fig. 6a,b). These
abnormalities were accompanied by an expansion of the external capsule (Fig. 6a,c,d;
arrows) and the anterior commissure (Fig. 6a,d; arrowheads). In addition, ectopic axon
bundles extended within the internal capsule toward the external capsule and continued to
grow ventrally (Fig. 6a,d).
We hypothesized that, in the absence of EphB1, the trajectories of subcerebral axons are
rerouted, abnormally crossing to contralateral targets via the anterior commissure. To test
whether the ectopic axon tracts were of neocortical origin, we anterogradely traced
neocortical output projections with the lipophilic tracer DiI injected in the sensorimotor
cortex of Ephb1−/− and wild-type littermates at P2. DiI labeled axons were found in the
corpus callosum and internal capsule in both wild-type and Ephb1−/− mice. However, only
in the mutant mice did we observe distinct DiI-labeled axons crossing at the anterior
commissure and extending ventrally and rostrally (Fig. 6e). In wild-type cortex, only
neurons located in the most lateral cortical areas, the posterior perirhinal cortex, and the
entorhinal cortex project contralaterally through the anterior commissure32. In the Ephb1−/−
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mice, however, neurons located in dorsal areas projected ectopically through this
commissure.
To confirm and visualize the axonal projection routes in the absence of EphB1, we used
high-angular-resolution diffusion imaging (HARDI) tractography to render a three-
dimensional image of major axon tracts in mutant and wild-type brains33,34. We found that
axon fibers in the dorsal areas of the neocortex merged with the anterior commissure in the
Ephb1−/− but not in wild-type brains (Fig. 6f). To identify a potential source of EphB1
ligands, we performed in situ hybridization for the ephrin genes Efnb1, Efnb2 and Efnb3.
We found that only Efnb3 was expressed at the ventral forebrain midline and thus might
mediate EphB1-dependent repulsion of ipsilateral descending tracts (Supplementary Fig.
12).
Reduced corticospinal tract in Ephb1 null mutants
To determine whether the corticospinal tract is specifically affected by EphB1 loss, we used
the Fezf2::PLAP (placental alkaline phosphatase) reporter line7 to genetically trace CSMN
axons in control (Ephb1+/−;Fezf2PLAP/+) and EphB1-deficient (Ephb1−/−;Fezf2PLAP/+) mice
at P7. In control mice, PLAP-positive axons were exclusively observed extending along
ipsilateral, corticofugal trajectories (Fig. 7a). In contrast, in EphB1-deficient mice, a large
proportion of PLAP-positive axons extended inappropriately to contralateral targets,
crossing the midline via an enlarged anterior commissure (Fig. 7b). Most notably, this
resulted in a drastic reduction of subcerebral axons reaching the cerebral peduncle (Fig. 7b)
and of corticospinal axons in the dorsal funiculus of the spinal cord (Fig. 7b). These results
demonstrate that, in the absence of EphB1, the ipsilateral axonal trajectories of the
corticospinal tract are compromised and a distinct proportion of axons take contralateral,
crossed routes through the anterior commissure.
It is notable that Fezf2−/− mutants also show loss of axonal projections to the cerebral
peduncle and the spinal cord (Fig. 7c and refs. 5–7), accompanied by an expansion of the
anterior commissure (Fig. 7c and ref. 7). This phenotype is reminiscent of that observed in
the EphB1-deficient mice (Fig. 7b and Supplementary Fig. 13). Beyond connectivity, in the
absence of Fezf2 the global fate specification of CSMN (molecular identity,
electrophysiological properties and connectivity to the spinal cord) is abolished5–7. In
contrast, we found that loss of EphB1 did not affect the fate specification of projection
neuron classes, which showed normal expression of the canonical projection neuron
subtype-specific markers CTIP2, TBR1, SATB2 and CUX1 (Supplementary Fig. 13). The
data indicate that EphB1 is an effector molecule directly downstream of Fezf2 that executes
a specific modular aspect of the global Fezf2−/− phenotype.
DISCUSSION
Deciphering the molecular logic that orchestrates the acquisition of neuronal subtype–
specific features in the mammalian cerebral cortex is fundamental to understanding how its
neuronal diversity has evolved. These molecular rules are not yet defined for any subtype of
cortical neuron. Here we report that acquisition of defining features of corticospinal motor
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neurons is at least partly achieved by co-regulated expression of batteries of CSMN effector
molecules directly downstream of a single selector gene, Fezf2.
Precise control over activation and repression of transcription factors responsible for
acquisition of class-specific traits in projection neurons is critical to resolve neuronal fates
during cortical development. Tbr1 and Sox5 act as repressors of Fezf2 to negatively regulate
the extension of the corticospinal tract and to promote connectivity to the thalamus35–38.
Similarly, reciprocal repression of Fezf2, Satb2 and Ctip2 is employed to choose subtype-
specific long distance connectivity39,40. These studies motivate a more global analysis of the
molecular rules beyond single genes that govern the acquisition of lineage-specific traits.
We found that expression of Fezf2 in cortical progenitors fated to generate upper layer
neurons resulted in both the induction of a large series of genes expressed in nascent CSMN
and the repression of molecular programs of upper layer neurons. Given that this
transcriptional regulation largely occurred via binding of Fezf2 to the promoters of both
activated and repressed genes, the data indicate that lineage bifurcation decisions can be co-
regulated by the same transcription factor from very early stages of differentiation. Our data
also provide a molecular explanation for why, during development, cortical progenitors tune
Fezf2 expression to the lower levels observed in late-stage cortical progenitors5,7,41.
Maintenance of Fezf2 expression after the completion of neurogenesis of deep layer neurons
may be molecularly incompatible with the initiation of upper layer neurogenesis.
Much work is still required to understand the nuances of how Fezf2 can act as an activator
for some target genes and as a repressor for others. It is likely that factors such as post-
translational modification of Fezf2, the choice of interacting cofactors and the presence of
neighboring binding sites for different proteins at different loci critically contribute to these
distinct transcriptional outcomes42.
Transcription factors endowed with properties of classic selector genes have been identified
in different tissues as genes uniquely able to control ‘master’ molecular switches of distinct
cellular fates. Elegant work in Drosophila has highlighted core properties of selector genes
that clarify the logic guiding their activity. Multiple target genes are often regulated
downstream of a single selector gene, and targets often include both activated and repressed
genes43. Our evidence that Fezf2 acts as both an activator of CSMN genes and a repressor of
genes for alternative fates further supports the idea that Fezf2 is a selector gene. To our
knowledge, this is the first transcription factor endowed with these properties for any class
of cortical neurons.
During development of CSMN, expression of lineage-specific and pan-neuronal genes alike
display temporally dynamic regulation. It is intriguing that within 48 h of induction, Fezf2 is
already associated with the promoters of CSMN genes whose expression is normally
temporally spaced during CSMN differentiation. The data suggest that, in cortical
progenitors, Fezf2 might be ‘priming’ the transcriptional territory of CSMN by also
occupying genomic loci that are transcriptionally active in these neurons at later times. This
implies that temporal resolution of gene expression over the several weeks of CSMN
development likely relies on cofactors that operate by interaction with Fezf2 or work on the
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genomic loci that are primed by early Fezf2 binding. The fact that Fezf2 expression is
maintained at all stages of CSMN differentiation in vivo5–7 supports the view that active
binding by Fezf2 to CSMN loci may be required to poise them for transcriptional regulation
at later stages of differentiation.
Precedents exist for the use of early priming of genomic loci in progenitor cells to enable the
execution of specific differentiation programs at later stages of development. In
Caenorhabditis elegans, asymmetric distribution of gene expression in bilaterally
symmetrical ASE gustatory neurons relies on early priming of the Isy-6 microRNA locus in
progenitors of only the left neurons44. MyoD has also been shown to associate with
enhancers of both early and late myogenic genes45.
In his first definition of selectors, Antonio García-Bellido postulated that these genes would
regulate effector molecules necessary for the acquisition of specific cellular features46. Here
we identify EphB1 as an effector molecule of Fezf2. In turn, EphB1 executes CSMN axonal
repulsion from the midline in the ventral telencephalon, enabling the ipsilateral extension of
the corticospinal tract. Our data are in agreement with work demonstrating a key role for
EphB1 in mediating midline repulsion decisions. In the spinal cord, EphB1 instructs the
ventral trajectory of motor neuron axons by mediating their repulsion from the mesenchyme
of the dorsal limb25. Similarly, in the optic chiasm, EphB1 mediates the repulsion of retinal
ganglion cell (RGC) axons from the midline47. Notably, in the retina the transcription factor
Zic2 is also upstream of genes critical for both axonal guidance decisions (EphB1) and
neurotransmitter identity (Sert)48.
The regulation of axon guidance molecules in different classes of cortical projection neurons
has just begun to be explored40. Whether expression of lineage-specific axon guidance
molecules is directly controlled by the same transcription factors that govern neuron subtype
fate specification remains unknown. It is striking that the phenotypic abnormalities observed
in the absence of EphB1 mimic the axon guidance defects observed in the Fezf2−/− mutants,
without affecting the overall fate specification of CSMN. While the possibility that
expression of EphB1 in thalamus or striatum contributes to this phenotype49 cannot be ruled
out, the fact that Fezf2 is not expressed in these regions and yet Fezf2−/− mice present
similar axon guidance defects to Ephb1 mutants supports a cell-autonomous role of EphB1
in CSMN. Our data point to a direct regulation of key CSMN axon guidance receptors by
the same selector gene that governs global programs of fate specification of this neuron
subtype.
Not all selector genes have equal properties. Pioneering work in C. elegans has identified
ones termed terminal selector genes sufficient to instruct specific neurotransmitter fates50.
Our data indicate that Fezf2 controls the acquisition of glutamatergic identity by direct
binding to the promoter of Vglut1 and other genes involved in the synthesis, transport and
signaling of glutamate. This is in agreement with the fact that overexpression of Fezf2 in
progenitors of GABAergic medium spiny neurons results in a switch to a glutamatergic fate
in vivo8. In addition, like selector genes in C. elegans, Fezf2 expression is maintained in
CSMN throughout life, suggesting a requirement for Fezf2 to both establish and maintain
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CSMN traits. In the future, conditional loss of Fezf2 in adult CSMN will test this possibility
and define the extent to which Fezf2 fulfills the definition of a canonical terminal selector.
An understanding of the molecular regulatory architecture that shapes the identity of CSMN
and other classes of cortical neurons is fundamental to gaining insights into how neuronal
diversity develops in the cerebral cortex and will furthermore inspire tools to reprogram
class-specific neuronal identity in the context of neurodegenerative disease.
ONLINE METHODS
Mice
Fezf2−/− mice were generated by Hirata et al.41 (Fezf2 GenBank accession code:
AB042399). Ephb1−/− mice (Ephb1 GenBank accession code: NM_173447) were generated
by Deltagen, Inc. (Menlo Park, CA). The line was generated by targeting the Ephb1 coding
region with a cassette containing a 4.5-kb homology sequence upstream of exon 8, a Lac0-
SA-IRES-lacZ-WT Neo/Kan cassette and a 2.2-kb homology sequence downstream of exon
8. The insertion of the Lac0-SA-IRES-lacZ-WT Neo/Kan cassette resulted in a 100-bp
deletion of genomic DNA. Sequences of PCR primers employed to genotype the Ephb1−/−
line are as follows: forward primer, ACGTGGGAGGACTCTAATCCTCTTC; reverse
primer (wild-type allele), TCTAGGTTGCTGGCTACAGGACTTG; reverse primer (Neo),
GGGCCAGCTCATTCCTCCCACTCAT. Fezf2::PLAP (Fezf2PLAP/+) mice were generated
by Chen et al.7 and crossed with the Ephb1+/− mutant line to obtain Ephb1−/−;Fezf2PLAP/+
mutants. Timed-pregnant CD-1 mice were obtained from Charles River Laboratories
(Wilmington, MA) for in utero electroporation. The day of the vaginal plug was designated
embryonic day 0.5 (E0.5). The day of birth was designated postnatal day 0 (P0). All mice
were maintained in standard housing conditions on a 12-h light/dark cycle with food and
water ad libitum. No more than four adult animals were housed per cage. All mouse studies
were approved by the Massachusetts General Hospital and Harvard University Institutional
Animal Care and Use Committee and were performed in accordance with institutional and
federal guidelines.
In utero electroporation
The Fezf2GFP and CtrlGFP construct and conditions for in vivo electroporation were
described previously5,51. The 3xFlag-Fezf2 open reading frame was cloned into the CtrlGFP
construct driven by the CAG promoter. Briefly, 800 nl of purified DNA (2 μg/μl) mixed
with 0.005% fast green in sterile PBS was injected in utero into the lateral ventricle of CD1
embryos at E14.5 under ultrasound guidance (Vevo 770, VisualSonics). Five 40-V pulses of
50 ms were delivered at 1-s intervals in an appropriate orientation across the embryonic
head using 1-cm-diameter platinum electrodes placed outside the uterus, using a
CUY21EDIT square wave electroporator (Nepa Gene). Injected embryos were collected for
FACS purification either 24 h or 48 h after electroporation.
FACS purification
Pregnant dams were deeply anesthetized 24 h or 48 h after surgery. Their embryos were
removed and sensorimotor cortex was microdissected, as previously described52, from the
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electroporated cerebral hemisphere using a fluorescence dissecting microscope to precisely
visualize the labeled regions. Fezf2GFP and CtrlGFP electroporated cells were purified by
FACS directly into RNAlater53 and RNA was extracted as previously described54. To
control for biological sample variability, we processed multiple independently collected
samples for both Fezf2GFP and CtrlGFP electroporated cells at each time point of analysis
(true biological replicates) for a total of fourteen samples derived from different litters,
FACS purifications and microarray hybridizations (three each of Fezf2GFP and CtrlGFP at
24 h and four each at 48 h). Fezf2GFP- and CtrlGFP-labeled cortical tissues were
enzymatically digested in dissociation medium (20 mM glucose, 0.8 mM kynurenic acid,
0.05 mM APV, penicillin-streptomycin (50 U/ml and 0.05 mg/ml, respectively), 0.09 M
Na2SO4, 0.03 M K2SO4 and 0.014 M MgCl2) containing L-cysteine HCl (0.016 μg/μl) and
papain (10 unit/ml; Worthington Biochemical Corp., NJ) at 37 °C for 30 min. Papain
digestion was stopped with ovomucoid (10 mg/ml) and BSA (10 mg/ml) in dissociation
medium at room temperature. Progenitors were mechanically dissociated to obtain a single-
cell suspension by gentle trituration in iced OptiMEM containing glucose (20 mM),
kynurenic acid (0.4 mM) and APV (0.025 mM). All chemicals were purchased from Sigma,
and all media were purchased from GIBCO-BRL. GFP-positive cells were purified using a
BD FACS Vantage SEM DiVa cell sorter. Cells were gated on the basis of on fluorescence,
forward scatter and side scatter to select the appropriate population. FACS-purified
progenitors and neurons from both time points were collected and stored in RNAlater before
RNA extraction53.
Microarray and analysis
Approximately 10,000 to 30,000 FACS-sorted progenitors were used for each biological
replicate. RNA was extracted using the StrataPrep Total RNA Micro Kit (Stratagene), and
RNA quality was assessed using a Bioanalyzer (Agilent Technologies). RNA was amplified
per Affymetrix small sample protocol using two consecutive rounds of linear in vitro
transcription to obtain 15–20 μg of amplified and labeled cRNA for each hybridization.
Microarray hybridization was performed with an Affymetrix Mouse Genome 430 2.0 Array
according to standard Affymetrix protocol55. For microarray experiments, 3 or 4 replicates
were used at each age, which allows the identification of differential gene expression with
low false discovery rates3.
Using the Rosetta Resolver software (Rosetta Biosoftware), data from individual
microarrays were normalized with the trend function and replicates were combined.
Statistical significance of gene expression differences between Fezf2GFP and CtrlGFP
experiments was determined by pairwise comparisons at each time point using the Rosetta
Resolver error modeling method56 with P-value limit of <0.001 and fold change of >1.5.
Similar results were obtained by normalizing with GCRMA in Bioconductor57 or with the
Bioconductor implementation of MAS 5.0 and performing pairwise comparisons using
significance analysis of microarrays (SAM)58.
For comparison with RNA-seq expression data from Ayoub et al.12, BAM files were
downloaded from NCBI (accession code GSE30765), differential expression was
determined with Cuffdiff, and analysis was performed with the Cummerbund package in the
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R language and environment for statistical computing and graphics59. From a list of genes
with significant differential expression between VZ, SVZ and cortical plate (P < 0.001) in at
least one sample, those with significant up- or downregulation induced by Fezf2 were
identified and subsequently used for cluster analysis with Jensen-Shannon divergence as the
distance metric in Cummerbund.
Western blot
Brains were dissected from P1 Ephb1 knockout, heterozygous and wild-type mice and lysed
in RIPA buffer (150 mM NaCl, 1% NP40, 0.5% deoxycholate, 0.1% SDS, 1 mM EDTA, 50
mM Tris-HCl, pH 8) with proteinase inhibitors (S8830, Sigma-Aldrich). Mouse ES cells
were treated with 2 μg/ml doxycycline for 48 h and harvested in RIPA buffer. After
quantification by Bio-Rad protein assay (Bio-Rad), proteins were resolved in 4–12% SDS-
PAGE gels and transferred to a nitrocellulose membrane. The western blot was performed
using goat anti-EphB1 (M19, Santa Cruz, 1:250), rabbit anti-Fezf2/Fezf1 (F441, IBL,
1:500), rabbit anti-β-tubulin (9F3, Cell Signaling, 1:500) and mouse anti-α-tubulin (T9026,
Sigma, 1:5,000). Anti-goat, anti-rabbit and anti-mouse HRP-conjugated secondary
antibodies (HRP-linked anti-rabbit IgG, Cell Signaling Technology 7074, HRP-conjugated
goat anti-mouse IgG, Cell Signaling Technology 7076, HRP-conjugated anti-goat IgG,
Santa Cruz sc-2020, all at 1:5000), followed by ECL (Amersham), were used to visualize
proteins of interest on the membrane.
Retrograde and anterograde labeling
Pups were anesthetized by hypothermia at P2 and injected with FluoroGold (for retrograde
labeling) in the contralateral cortex or the pons, or with DiI (for anterograde labeling) in the
motor cortex as previously described17,60. The site of DiI injection was identified by
ultrasound guidance. Pups were returned to the care of their mother and deeply anesthetized
at P4 and P7 in the retrograde tracer studies, and at P4 for the anterograde tracer study,
before perfusion and collection of the brain for immunocytochemistry.
High-angular-resolution diffusion imaging (HARDI)
Four-week-old (P28) wild-type and Ephb1−/− littermates were perfused with saline followed
by 4% paraformaldehyde, postfixed for 24 h, and subsequently fixed for an additional week
in 4% paraformaldehyde solution containing 1 mM gadolinium (Gd-DTPA). For image
acquisition, the brains were placed in Fomblin. Brains were scanned on a 4.7-T Bruker
Biospec MR system. The pulse sequence used for image acquisition was a 3D diffusion-
weighted spin-echo echo-planar imaging sequence, time repetition (TR)/time echo (TE)
1,000/45.47 ms, with an imaging matrix of 96 × 96 × 128 pixels. Spatial resolution was 125
× 125 × 125 μm. Sixty diffusion-weighted measurements (b = 4,000 s/mm2) and one non-
diffusion-weighted measurement (b = 0) were acquired with δ = 12.0 ms, Δ = 24.2 ms. Total
acquisition time was approximately 2 h for each imaging session. The HARDI method was
used to reconstruct the orientation distribution function in each voxel and resulting
tractography pathways were reconstructed using a streamline algorithm for diffusion
tractography33,61 Diffusion Toolkit and TrackVis (http://trackvis.org/) were used to
reconstruct and visualize axonal pathways. Trajectories were propagated by consistently
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pursuing the orientation vector of least curvature, and tracking was terminated when the
angle between two consecutive orientation vectors was greater than the given threshold of
45° for each specimen. Brain mask volumes created by MRIcro (http://
www.mccauslandcenter.sc.edu/mricro/mricro/mricro.html) were used to terminate
tractography structures instead of the FA (Fractional Anisotropy) threshold as previously
reported61,62. Commissural pathways were isolated as fibers passing through the manually
drawn region of interest that included the entire anterior commissure at the midline, ensuring
that other fiber pathways were not contributing, as previously described61.
Immunocytochemistry, PLAP staining and in situ hybridization
Brains for immunocytochemistry were processed as previously described55,63. Primary
antibodies and dilutions used were as follows: rabbit anti-TBR1 antibody, 1:2,500 (gift from
R. Hevner); rat anti-CTIP2 antibody, 1:1,000 (Abcam ab18465); rabbit anti-GFP, 1:500
(Invitrogen A11122); chicken anti–β-galactosidase, 1:500 (ICL lab CGAL-45A); mouse
anti-SATB2, 1:50 (Abcam ab51502); rat anti-MBP, 1:500 (Millipore MAB386); and rabbit
anti-CUX1, 1:100 (Santa Cruz CDP M-222). Goat anti-rabbit IgG Alexa Fluor 488, 546, and
647 (Life Technologies A11070, A-11071, A21246), Goat anti-chicken IgG Alexa Fluor
488, 546, 647 (Life Technologies A11039, A11040, A21449), Goat anti-rat 488, 546, 647
(Life Technologies A11006, A11081, A21247), Goat anti-mouse IgG Alexa Fluor 488, 546,
647 (Life Technologies A11017, A11018, A21237) secondary antibodies were diluted
1:750. PLAP activity was detected with alkaline phosphatase staining buffer (0.1 mg/ml 5-
bromo-4-chloro-3-indolyl phosphate; 1 mg/ml nitro blue tetrazolium in 100 mM Tris-HCl,
pH 9.5; and 100 mM NaCl) as previously described7. In situ hybridization and combined in
situ hybridization with immunohistochemistry were performed following published methods
and using 40-μm-thick sections cut on a vibrating microtome and mounted on Superfrost
slides (Fisher)64. Riboprobes were generated as previously described54. The cDNA template
clone for Ldb2 was provided by J. Macklis; all other riboprobes were generated from cDNA
template clones using the primers listed below. Tissue sections were imaged using a Nikon
90i fluorescence microscope equipped with a Retiga Exi camera (Q-Imaging) and analyzed
with Volocity image analysis software v4.0.1 (Improvision). All primary data from
immunohistochemistry and in situ hybridization experiments were repeated at least three
times and analyzed by one investigator, then confirmed by a second, independent
investigator who was blinded to genotype and experimental conditions.
In situ hybridization riboprobe templates
cDNA templates for riboprobes were obtained by RT-PCR with the following primer pairs:
Gene name Forward primer Reverse primer Product length
Acvr1c AGGACTTGCCTCGAAAGTGA GAAAGCAGAAGCGGACATTC 610
Adcyap1 AATGACTTGGGGAATTGCTG GCATGAACAGCACTGGAGAA 542
Akap12 GTTGGGACCTTGAGACCAAA TGGCACACTCATCTGTCCAT 691
C1ql3 AGTGTGGTCCTTCACCTGGA CAAGAACCAAAGCTGACACG 507
Cntn6 GTATCTGTCCGAGAAGGTCA GTGGACCTTGGACACTTCTA 238
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Gene name Forward primer Reverse primer Product length
Ephb1 CACATCCATCTCCCTTTGCT TCCAGAAACCCTTTCCCTCT 618
Efnb1 ACAAGCCACACCAGGAAATC TGGGGGCAGTAGTTGTTCTC 640
Efnb2 ACCACACAGCTATGCAGCAG CGAACTCCACGTCTTCTGGT 675
Efnb3 GCAGTGTGGACATGATGGAC GCACACTAAAGAGCGGGAAG 675
Kif26a TCCTCAGCTCCAGACTCCAT GCGACAGTCTTTCCATCTCC 851
Pappa2 CCATTGTTCCACAAATGCTG CTCGCTCCACATGTTGCTTA 900
Parm1 TGCACTGACCAAGCCAGATA ACAAACAGCAAGGCAGTGAA 700
Rgs16 AAAAGGCTGTGTGTGTGGAAC CTATCACTTCTGAGTCTTACCG 752
Rgs8 TGAGGTCATGTTTGGGTTCA CAGGCTCTACGGACTTCTGG 741
Tmem163 AGGGTCTCTGCTTGACAGGA CCCTACATGTTGGCACACAC 650
Tshz2 GGCGAAGAGGACACAGACTC AAGGAGCGCTGTCGATAAAA 710
Tmem117 AACTATGCCACAACGGTGCT TTGTAGACAGTGGGCTGTGC 754
Neurosphere isolation and viral infection
Primary cortical progenitors of the dorsal telencephalon were isolated from E14.5 brains and
grown as neurospheres in the presence of growth factors as previously reported65.
Neurospheres were expanded for a maximum of one passage and then plated as a monolayer
on dishes coated with poly-D-lysine (VWR) and laminin (BD). E14.5 pregnant dams were
deeply anesthetized and the embryos removed. The presumptive somatosensory area was
microdissected in cold Hanks’ medium and mechanically triturated to obtain a single-cell
suspension. Cells were spun at 5,000g for 5 min at room temperature, and the pellet was
resuspended in neurosphere medium, containing 100 U/ml penicillin/streptomycin, 200 mM
L-glutamine, N2 and B27 supplements (Gibco), as well as 20 ng/ml epidermal growth factor
(EGF; Sigma) and 20 ng/ml β-fibroblast growth factor (FGF; Millipore) in order to promote
the survival of neural stem cells. After quantification of cell density, neural stem cells were
plated in 200-ml tissue culture flasks (untreated or low-adherence, Corning) at 200,000
cells/flask and incubated at 37 °C with 5% CO2. The medium was changed every 3–4 d and
the cells were expanded as neurospheres for one passage. Subsequently, cells were plated as
a monolayer on dishes previously coated with poly-D-lysine (VWR) and laminin (BD).
3xFlag-Fezf2 and 3xFlag were cloned into pRETROX-IRES-ZsGreen1 retroviral vectors
(Clontech Laboratories, Inc.) to generate high-titer, replication-incompetent, VSVg-coated
retroviral particles that were packaged in 293T cells (MOI = 5). 12–18 h after plating, neural
stem cells were infected with retroviruses. 16–203h after infection, cells were switched into
fresh medium. Cells were collected 48 h after infection for chromatin immunoprecipitation
(ChIP, n = 2) and for RNA-seq (n = 2). Sample sizes for ChIP-seq and RNA-seq
experiments on neural progenitors complied with the ChIP-seq ENCODE guidelines66.
Chromatin immunoprecipitation (ChIP)
ChIP analysis was performed on 1.5 × 108 neural stem cells per condition (3xFlag-
Fezf2ZsGreen1 and 3xFlagZsGreen1, 2 replicates each) as previously described67. Briefly, cells
were dissociated with 0.25% trypsin (Invitrogen), washed with PBS and chemically cross-
linked with formaldehyde solution (1%). Cells were disrupted in lysis buffer (50 mM Tris,
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pH 8.0; 10 mM EDTA; 1% SDS; and protease inhibitors) for 20 min on ice and sonicated
with a Bioruptor to shear the DNA into 200–700 bp fragments. Dynal magnetic beads (sheep
anti-mouse M-28, Invitrogen) were preblocked with 5 μg of anti-Flag M2 antibody per
reaction (Sigma-Aldrich) rotating overnight at 4 °C. Beads were then washed and
resuspended in fresh 0.5% BSA in PBS. Bead-antibody complexes were incubated at 4 °C
overnight with rotation. Beads were resuspended twice in low-salt immune complex wash
buffer (0.1% SDS; 1% Triton X-100; 2 mM EDTA; 20 mM Tris-HCl, pH 8.1; and 150 mM
NaCl), incubated for 5 min at 4 °C with rotation and resuspended in LiCl immune complex
wash buffer (0.25 M LiCl; 1% NP40; 1% deoxycholate; 1 mM EDTA; and 10 mM Tris-
HCl, pH 8.1) twice and incubated for 5 min at 4 °C with rotation. Beads were then rinsed
with ice-cold 10mM Tris-HCl; 1mM EDTA, pH8.0 and DNA was eluted in 100 μl of elution
buffer (50mM Tris-HCl; 10mM EDTA; 1%SDS, pH 8.0) at 65 °C for 15 min. Reverse
crosslinking was performed by incubating the ChIP DNA overnight at 65 °C. DNA was
purified on QIAquick PCR purification columns (Qiagen) for use as template for Solexa
library construction. To prepare an input control, whole-cell-extract DNA (reserved from the
sonication step) was also treated by reverse crosslinking and purified.
ChIP-seq data analysis
For both ChIP-seq replicates, high-throughput sequencing reads were aligned to the mouse
genome (version mm9) using Bowtie version 0.12.5 with options “-q --best --strata -m 1 -p 4
--chunkmbs 1024,” and only uniquely mapping reads were retained for further analysis.
GEM was used to detect binding events, using the options “--top 2000 --k_min 7 --k_max
12 --a 20 --q 3 --mrc 1 - constant_model_range --d_l 1000 --d_r 1000 --v 2 --nf --
refine_pwm --gc0 0.42.” Reported peaks contain a ChIP-seq enrichment level that is
significantly greater than 1.5 times the scaled read count from the corresponding region in
the control experiment (P < 10−6, binomial test, adjusted for multiple testing using
Benjamini & Hochberg’s method). GPS (genome positioning system) was also used to
confirm binding locations, using the options “--top 2000 --a 20 --q 3 --mrc 1 --
constant_model_range.” Regions of ChIP enrichment (1 Kbp) are highlighted in red or blue,
centered on the GEM-predicted binding event locations. De novo motif discovery was also
performed using GEM, which jointly estimates binding locations and primary DNA motif
patterns. Motif frequencies at binding events and gene promoter regions were defined by
scanning 100-bp windows around GPS binding locations or annotated TSSs for matches to
each motif. Motif scoring thresholds were based on a false discovery rate of 10−3, defined
using a third-order Markov model of the mouse genome. Comparison between peaks and
gene features was performed using the Ensembl v62 mouse genome annotation. Genes were
defined as bound if a Fezf2 binding event was located within 5 kb of a gene’s TSS. A chi-
squared test was used to assess the significance of associations between Fezf2 binding and
groups of differentially regulated genes in vivo.
RNA-Seq library preparation
Total RNA was isolated using QIAzol (Qiagen)/chloroform extraction followed by spin-
column purification (RNeasy mini kit, Qiagen) according to the manufacturer’s instructions.
RNA concentration and purity were measured with Nanodrop (Thermo Fisher), and RNA
integrity was assessed on a Bioanalyzer (Agilent) using the RNA 6000 Nano Total RNA kit
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(Agilent). High-quality RNA samples (RNA integrity number ≥ 8) were used for library
preparation. Poly(A)+ RNA-seq libraries were constructed using the TruSeq RNA Sample
Preparation Kit (Illumina) following the manufacturer’s protocol. 200 ng of total RNA from
neurospheres was used as input for the TruSeq libraries. Before sequencing, libraries were
run on a Bioanalyzer DNA7500 chip to assess purity, fragment size and concentration.
Libraries free of adaptor dimers and with a peak region (220–500 bp) area ≥80% of the total
area were sequenced. Individually barcoded samples were pooled and sequenced on the
Illumina HiSeq 2500 platform.
RNA-Seq analysis
Paired-end 101-bp reads were aligned to the mouse (mm9) reference genome assembly
using Tophat2 (refs. 68,69) with default options. Aligned reads and the UCSC reference
transcriptome .gtf file (UCSC genome browser; knownGene track) were used as input for
Cuffdiff2 (ref. 70) for expression quantification in fragments per kilobase RNA per million
mapped reads (FPKM) and differential testing between conditions using default options (P <
0.001). Cummerbund v2.1 (http://compbio.mit.edu/cummerbund/) was then used to process,
index and visualize the output of the Cuffdiff2 analyses.
To test for enrichment for CSMN signature genes after Fezf2 overexpression in cortical
progenitors, we performed a preranked gene set enrichment analysis (GSEA). Briefly,
CSMN signature genes were selected from Arlotta et al.54 as the intersection of genes
flagged as ‘present’ (Affymetrix; RMA) with a fold-change of CPN/CSMN ≤1/3 from the
P3 and P6 time point comparisons. Inversely, CPN signature genes were created from the
intersection of genes with a fold-change of CPN/CSMN ≥3 from the same two time points.
Additional gene sets consisting of the subset of each gene list that was also selected as
Fezf2-bound from our ChIP-Seq study were created.
We next created a ranked gene list of all expressed genes (FPKM ≥ 1) from our 3xFlag-
Fezf2ZsGreen1 versus 3xFlagZsGreen1 cortical progenitor RNA-Seq assay. Expressed genes
were rank-ordered using the value of the Cuffdiff2 test statistic. All derived gene sets were
tested for enrichment or depletion after Fezf2 overexpression using the preranked GSEA
approach71. CSMN signature and CSMN signature plus Fezf2-bound gene sets were
determined to be significant with a nominal P value ≤ 0.01.
Gene ontology enrichment analysis was performed on Fezf2-induced genes with specific
expression in the cortical plate (as determined by Ayoub et al.12) and Fezf2-repressed genes
with specific expression in either the VZ or SVZ/IZ using DAVID72. Genes within each
gene set were selected using a threshold specificity score S ≥ 0.65 (described below) for any
given condition. Gene sets were tested for significant enrichment using the GO Biological
Process FAT collection of gene sets.
We defined the specificity score Sgi for a gene (g) in a condition (i) as follows:
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where JSD is the Jensen-Shannon divergence between pg, the expression profile of a gene g
across all conditions expressed as a probability distribution, and qi, the unit vector of perfect
expression in condition i. Where applicable, genes are specifically assigned to the condition
with the highest S score above a threshold value. The threshold for specificity was selected
empirically to be 0.65 through examination of the distribution of S scores across all genes.
Hypergeometric and bootstrap analyses
To determine enrichment for Fezf2-bound genes within the set of significantly differentially
regulated genes in the E14.5 cortical neurospheres, we employed a hypergeometric test
(phyper from the stats package in R) and a bootstrap method. For the bootstrap method, gene
sets of comparable size were sampled (without replacement) from the universe of genes
10,000 times, and P values were estimated as the fraction of iterations where a greater than
or equal number of Fezf2-bound genes were selected.
Derivation and differentiation of inducible Fezf2 and GFP mouse ES lines
Mouse Fezf2-IRES-GFP was PCR-cloned from the Fezf2GFP construct5 into P2lox-40 using
the Gateway system (Life Technologies). The control GFP construct was a gift from E.
Mazzoni73. The plasmid constructs were nucleofected into the A2loxCRE mouse ES line for
inducible cassette exchange (ICE) as described in Iacovino et al.74 The cells were selected
on DR4 mouse embryo fibroblasts (GlobalStem) with 300 μg/ml G418. Single inducible
Fezf2-IRES-GFP (iFIG) clones and inducible GFP (iGFP) clones were manually picked and
expanded in standard ES+LIF medium without doxycycline (15% FBS, 1× Glutamax, 1×
non-essential amino acids, 1× penicillin/streptomycin and 1,000 U/ml mLIF (ESGROW,
Millipore) in Knockout DMEM). All media were obtained from GIBCO BRL. The iFIG and
iGFP clones were differentiated in vitro into cortical neurons using the SFEBq protocol as
described in Eiraku et al.75 Expression of Fezf2 and GFP was induced at day 10 in vitro
with 2 μg/ml doxycycline. The doxycycline was maintained in the culture until day 18, and
the SFEBqs were dissociated and FACS-sorted for GFP+PI− populations, which were then
analyzed by RNA-seq.
Electrophoretic mobility shift assay (EMSA)
GST-tagged truncated mouse Fezf2 (GST-tFezf2, AA291-455) protein was expressed in
Rossetta DE3 E. coli (Millipore) and purified on GST-agarose with standard methods. Given
that the full-length Fezf2 aggregates in solution, we chose a truncated version of Fezf2
(tFezf2) containing five of the six zinc finger motifs in the C-terminal domain of Fezf2,
highly conserved across all vertebrates. IRDye end-labeled oligonucleotide probes
(Integrated DNA Technologies) were designed against proximal promoter regions under
ChIP-seq peaks of the Ascl1 and Ephb1 genes. Negative controls for each gene were chosen
from neighboring sequences not containing ChIP-seq peaks. The probe sequences are as
follows (with GEM motifs underlined):
Ephb1 positive probe:
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GCCGAGCCCCAGCGGAGACGCGCCGCGTCCCAGGGCGCCGCTGCGCTCCCGGC
GGGTGGCTAGCCACCCGCCGGGAGCGCAGCGGCGCCCTGGGACGCGGCGCGTC
TCCGCTGGGGCTCGGC.
Ephb1 negative probe:
TGTCAGAAGACAGTCATAATGGGAAGACATGAAGAAACAGCCGAAAGTCTGAC
AACTTGTTAACAAGTTGTCAGACTTTCGGCTGTTTCTTCATGTCTTCCCATTATG
ACTGTCTTCTGACA.
Ascl1 positive probe:
GCTCTGAGCTGCCGCGGCCGCCGCCGCTGCCGCCGCCGCCGCGGTCGCAAAGAA
GCAGGCGCCTGCTTCTTTGCGACCGCGGCGGCGGCGGCAGCGGCGGCGGCCGC
GGCAGCTCAGAGC.
Ascl1 negative probe:
CCTAGTGGTTATTTTATTGCTGTAAAATAAATTTAACCCTTTCCTTACCAAGCTG
CTTTTAAAAGCAGCTTGGTAAGGAAAGGGTTAAATTTATTTTACAGCAATAAAA
TAACCACTAGG.
EMSA was performed using the Odyssey EMSA Kit (LI-COR Biosciences, USA),
following the manufacturer’s protocols. Briefly, 100 nM IRDye end-labeled probe was
incubated with 0, 10 or 20 μg GST-tFezf2 at room temperature for 30 min in 20 μl reaction
buffer (1× binding buffer, 0.2 mM DTT, 0.25% Tween 20, 0.05 μg/μl poly(dI.dC) and 5 mM
MgCl2). The reactions were resolved on 4–20% Mini-PROTEAN TBE precast gel (Bio-
Rad) and visualized by the Odyssey CLx infrared imaging system (LI-COR Bioscience,
USA).
Statistics
Bar and line graphs represent mean values of all replicates and error bars represent s.e.m.
except for RNA-seq results, in which the error bars represent 95% confidence intervals for
the Cuffdiff2 model expression estimate. Animals were assigned to groups on the basis of
genotype. Age-matched littermates were used as controls in all experiments. No
randomization was used. For all animal experiments, data distribution was assumed to be
normal, but this was not formally tested. For ISH and immunofluorescence studies, data
collection and analysis were performed blinded to the conditions of the experiment. No
animals were excluded from analyses. Except for RNA-seq and ChIP-seq sample sizes
(explained above), no statistical methods were used to predetermine sample sizes. Our
sample sizes are similar to those reported in previous publications3.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Fezf2 overexpression in cortical progenitors induces genes that label corticospinal motor
neurons. Left, in situ hybridizations on coronal sections of the cerebral cortex at different
embryonic (E15.5, E17.5 and E18.5) and postnatal stages (P3, P7 and P14) (insets enlarged
from boxed areas). Right, expression levels (normalized microarray intensity, see Methods)
for each selected gene in CtrlGFP (blue) and Fezf2GFP (red) in utero electroporated cortical
progenitors that were collected at 24 h (n = 3 litters per condition) and 48 h (n = 4 litters per
condition). Vertical axes are normalized intensities (arbitrary units). Error bars indicate
s.e.m. LV, lateral ventricle; Str, striatum. Scale bars, 100 μm; 50 μm in insets. Source data
are shown in Supplementary Table 1.
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Figure 2.
Fezf2-induced genes identify native CSMN and label subsets of the broad CTIP2-positive
population in layer V. (a) In situ hybridization showing expression of Adcyap1 in E13.5
cortical progenitors (left) and young postmitotic subcerebral neurons in developing cortical
plate (middle and right). (b–d) Immunocytochemistry for CTIP2 combined with in situ
hybridization for Adcyap1, Kif26a and Tmem163 (boxed area enlarged in panel to the right).
Examples of double-positive cells (arrowheads) are indicated in the right column. CP,
cortical plate; LGE, lateral ganglionic eminence; LV, lateral ventricle; Str, striatum. Scale
bars, 100 μm (a; b–d left panels), 20 μm (b–d, middle panels), 10 μm (b–d, right panels).
The complete gene list is given in Supplementary Table 3.
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Figure 3.
Genome-wide binding analysis for Fezf2 shows preferential association with proximal
promoter regions of CSMN genes. (a) Fezf2 binding events preferentially occur in proximity
to promoter regions, within 5 kb of the TSS of annotated genes. (b–i) Examples of 3xFlag-
Fezf2 peaks at proximal promoters for early (Sox5 and Ctip2; b,c), middle (Crim1) (d) and
late (Pcp4, Opn3, Diap3, S100a10 and Cdh22; e–i) CSMN genes. In situ hybridizations are
shown for Crim1 (P21), Pcp4 (P21), Opn3 (P21), S100a10 (P21), Diap3 (P14) and Cdh22
(P21). Immunohistochemistry results are shown for SOX5 (E18.5) and CTIP2 (P1). Scale
bars, 100 μm (b–i). (j) The “zero cross” area represents genes where the Cuffdiff2 test
statistic is equal to 0 and no appropriate rank information is available. The color scales used
for the rank density represent kernel density estimate of gene rank positions (white = 0, red/
blue=max density). GSEA for CSMN and CPN signature gene sets. Signature gene sets (in
red) and the corresponding subsets bound by Fezf2 (in blue) were assessed for enrichment in
Fezf2-overexpressing neurospheres. Both CSMN signature genes and the subset bound by
Fezf2 were significantly enriched in Fezf2-overexpressing neurospheres. Neither set of CPN
signature genes showed significant enrichment. Source data are shown in Supplementary
Table 4.
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Figure 4.
Fezf2 promotes glutamatergic and inhibits GABAergic neurotransmitter pathways. (a)
ChIP-seq trace shows that 3xFlag-Fezf2 binds specifically to the promoters of Vglut1
(Slc17a7) and Gad1 but not Vglut2 (Slc17a6). (b) RNA-seq analysis shows the effect of
3xFlag-Fezf2 overexpression on these three genes in neural stem cells in vitro. (c) Inducible
expression of single-copy Fezf2-IRES-GFP is show by immunoblotting and fluorescence
microscopy. Uncropped original immunoblots are shown in Supplementary Figure 10. (d)
Schematic representation of directed differentiation protocol used to instruct embryonic
stem cell (ES) differentiation into mixed populations of cortical neurons23. (e) RNA-seq
analysis showing the effect of Fezf2 expression on Vglut1, Vglut2 and Gad1 in ES-derived
neurons. Clones used for RNA-seq were from the differentiation of n = 2 independently
generated iGFP and n = 2 iFIG lines. the error bars represent 95% confidence intervals for
the Cuffdiff2 model expression estimate as defined in Methods and described in Trapnell et
al., 2013.
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Figure 5.
Fezf2 controls Ephb1 selective expression in CSMN by direct association with the Ephb1
promoter. (a) In situ hybridization for Ephb1 in the forebrain at different stages of
embryonic and postnatal development shows highest expression in developing cortical plate
at E15.5, the time of initial CSMN axonal extension, and its restricted expression in
developing layer V, until approximately E18.5. (b) In situ hybridization for Ephb1 and
immunocytochemistry for TBR1 and APC show maintained expression of Ephb1 at
postnatal stages in corticothalamic neurons (TBR1-positive in layer VI) and
oligodendrocytes (APC-positive). (c) β-galactosidase immunocytochemistry in Ephb1
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heterozygous mice at P1 shows that, within layer V, expression colocalizes with CTIP2, and
not with SATB2 (arrows upper panel). The dotted rectangle area in the left panel is shown in
high magnification in the four panels on the right. Retrograde labeling of ScPN from the
pons of P1 Ephb1 heterozygous mice shows colocalization of FluoroGold with β-
galactosidase in layer Vb (arrows). Retrograde labeling of CPN in P2 Ephb1 heterozygous
mice shows no colocalization of FluoroGold with β-galactosidase in callosal neurons of
layer Va (arrowheads). Confocal images of layer V were combined to produce three-
dimensional reconstructions (Lower right panels). Sidebars represent projections along the
x–z axes (right) and the y–z axes (below). (d) Left, in situ hybridization for Ephb1 on E18.5
wild-type (left inset) and Fezf2−/−(right inset) littermates shows that Ephb1 levels
specifically decrease in layer V of the mutant cortices. Right, DNA regions spanning 5′ UTR
and first exon of the Ephb1 gene show enrichment of 3xFlag-Fezf2 binding (q = 10−15)
compared to control. Str, striatum. Scale bars, 100 μm (a; c, far left panels), 20 μm (b), 50
μm (c, top right panels; d), 20 μm (c, bottom right panels).
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Figure 6.
Cortical neurons aberrantly project through the anterior commissure in absence of EphB1.
(a–d) Immunocytochemistry for myelin basic protein (MBP) on coronal sections of P28
wild-type and Ephb1−/− littermates shows internal capsule reduction and defasciculation,
accompanied by an expansion of both the external capsule (arrows) and the anterior
commissure (arrowheads). (e) DiI anterograde injections in deep layers of the
somatosensory cortex of P2 wild-type (n = 3) and Ephb1−/− (n = 3) pups show axons
ectopically crossing at the anterior commissure and extending ventrally and rostrally (red
arrows) in the Ephb1 mutants but not in wild-type animals. (f) Color-coded three-
dimensional reconstructions based on HARDI of P28 wild-type and Ephb1−/− littermates
show distinct axon fibers originating in dorsal areas of the neocortex merging abnormally
with the anterior commissure in the Ephb1−/− (top right) compared to wild-type (top left)
brains. Red represents the anterior–posterior direction; green represents the medial–lateral
direction; blue represents the dorsal–ventral direction. Green arrows indicate axon tracts
penetrating into the cortex. AC, anterior commissure; ACa, anterior part of the anterior
commissure; ACp, posterior part of the anterior commissure; cc, corpus callosum; dCtx,
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dorsal cortex; lCtx, lateral cortex; EC, external capsule; IC, internal capsule. Scale bars: 50
μm (a), 20 μm (b–d) 100 μm (e).
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Figure 7.
Ephb1−/− mice recapitulate the axon guidance phenotype observed in Fezf2 null mutants.
(a–c) PLAP-positive axons inappropriately project through the anterior commissure in
Ephb1−/− mutants (b, arrows), mimicking the Fezf2PLAP/PLAP axonal phenotype (c,
arrows). Enlargement of the anterior commissure in Ephb1−/− mice is accompanied by a
reduction of PLAP-positive axons found in the cerebral peduncle (b, middle panel) and the
cervical spinal cord (b, bottom), canonical targets of the corticospinal tract in wild-type mice
(a, middle and bottom). No axons are found in the cerebral peduncle or spinal cord of the
Fezf2PLAP/PLAP mice (c, middle and bottom). AC, anterior commissure; Cp, cerebral
peduncle; Hp, hippocampus; CST, corticospinal tract. C6, cervical vertebra. Scale bars: 100
μm (a–c, top panels), 50 μm (a–c, middle and bottom).
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